Acadia Pharmaceuticals
![Acadia plans a Phase III study for a Prader-Willi syndrome candidate following an FDA meeting](https://pharmtales.com/wp-content/uploads/2023/06/Acadia-plans-a-Phase-III-study-for-a-Prader-Willi-syndrome-candidate-following-an-FDA-meeting.jpg)
Acadia plans a Phase III study for a Prader-Willi syndrome candidate following an FDA meeting
SG Tylor
Source – Acadia Pharmaceuticals ACP-101, also known as intranasal carbetocin, has been chosen by Acadia to move forward into a ...